Liposomes for HIV prophylaxis

Biomaterials

Volumn 32, Issue 33, 2011, Pages 8663-8668

  Malavia, Nikita K ^a,b   Zurakowski, David ^a   Schroeder, Avi ^b   Princiotto, Amy M ^c,d   Laury, Anna R ^e   Barash, Hila E ^a,b   Sodroski, Joseph ^c,d   Langer, Robert ^b   Madani, Navid ^c,d   Kohane, Daniel S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AIDS; Cardiolipin; HIV; Liposome; Prophylaxis

Indexed keywords

AIDS; CARDIOLIPINS; HIV; HIV INFECTION; HIV-1 INFECTIONS; HIV/AIDS; IN-VIVO; MICROBICIDES; MOUSE MODELS; PHYSICOCHEMICAL PROPERTY; PROPHYLAXIS; SEXUAL INTERCOURSE; SYNTHETIC LIPID; THERAPEUTIC INDEX; TISSUE REACTIONS;

LIPOSOMES; PHOSPHOLIPIDS; TISSUE; VIRUSES;

DISEASES;

CARDIOLIPIN; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VIVO STUDY; INFECTION PREVENTION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TISSUE REACTION; TREATMENT OUTCOME; ZETA POTENTIAL;

ANIMALS; BIOCOMPATIBLE MATERIALS; FEMALE; HIV INFECTIONS; HUMANS; LIPOSOMES; MICE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052963865     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.068     Document Type: Article

References (27)

1. Fauci A.S. 25 years of HIV. Nature 2008, 453(7193):289-290.
2. Fauci A.S. Pathogenesis of HIV disease: opportunities for new prevention interventions. Clin Infect Dis 2007, 45(4):S206-S212.
3. Berkhout B., Paxton W.A. HIV vaccine: it may take two to tango, but no party time yet. Retrovirology 2009, 6:88.
4. Burton D.R., Weiss R.A. AIDS/HIV. A boost for HIV vaccine design. Science 2010, 329(5993):770-773.
5. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., et al. Whither or wither microbicides?. Science 2008, 321(5888):532-534.
6. Hendrix C.W., Cao Y.J., Fuchs E.J. Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol 2009, 49:349-375.
7. Klasse P.J., Shattock R.J., Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med 2006, 3(9):e351.
8. Pope M., Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003, 9(7):847-852.
9. Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antivir Res 2010, 85(1):142-158.
10. Li Q., Estes J.D., Schlievert P.M., Duan L., Brosnahan A.J., Southern P.J., et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458(7241):1034-1038.
11. O'Keefe B.R., Vojdani F., Buffa V., Shattock R.J., Montefiori D.C., Bakke J., et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 2009, 106(15):6099-6104.
12. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009, 8(6):526-533.
13. McGowan I. Microbicides for HIV prevention: reality or hope?. Curr Opin Infect Dis 2010, 23(1):26-31.
14. Larsen C.E., Nir S., Alford D.R., Jennings M., Lee K.D., Duzgunes N. Human immunodeficiency virus type 1 (HIV-1) fusion with model membranes: kinetic analysis and the role of lipid composition, pH and divalent cations. Biochim Biophys Acta 1993, 1147(2):223-236.
15. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 2002, 41(1):27-65.
16. Konopka K., Davis B.R., Larsen C.E., Alford D.R., Debs R.J., Duzgunes N. Liposomes modulate human immunodeficiency virus infectivity. J Gen Virol 1990, 71(Pt 12):2899-2907.
17. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(2):145-160.
18. Sivan S., Schroeder A., Verberne G., Merkher Y., Diminsky D., Priev A., et al. Liposomes act as effective biolubricants for friction reduction in human synovial joints. Langmuir 2010, 26(2):1107-1116.
19. Madani N., Perdigoto A.L., Srinivasan K., Cox J.M., Chruma J.J., LaLonde J., et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004, 78(7):3742-3752.
20. Madani N., Schon A., Princiotto A.M., Lalonde J.M., Courter J.R., Soeta T., et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008, 16(11):1689-1701.
21. Schon A., Madani N., Klein J.C., Hubicki A., Ng D., Yang X., et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006, 45(36):10973-10980.
22. Finney D.J. Probit analysis 1971, Cambridge University Press, New York. 3rd ed.
23. Catalone B.J., Kish-Catalone T.M., Budgeon L.R., Neely E.B., Ferguson M., Krebs F.C., et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004, 48(5):1837-1847.
24. Microbicides GC. Announcing the results of PRO 2000. 2009; available from: http://www.global-campaign.org/.
25. Center for the AIDS Programme of research in South Africa (CAPRISA). Study of microbicide gel shows reduced risk of HIV & Herpes infections in women. XVIII International AIDS conference. Viennna, Austria, 2010.
26. Ndesendo V.M., Pillay V., Choonara Y.E., Buchmann E., Bayever D.N., Meyer L.C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 2008, 9(2):505-520.
27. du Toit L.C., Pillay V., Choonara Y.E. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv Drug Deliv Rev 2010, 62(4-5):532-546.